Sphera Funds Management LTD. Takes Position in Spark Therapeutics Inc (ONCE)

Sphera Funds Management LTD. purchased a new stake in shares of Spark Therapeutics Inc (NASDAQ:ONCE) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 100,000 shares of the biotechnology company’s stock, valued at approximately $5,142,000. Sphera Funds Management LTD. owned approximately 0.27% of Spark Therapeutics at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Ameritas Investment Partners Inc. lifted its holdings in shares of Spark Therapeutics by 23.6% during the second quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 389 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Spark Therapeutics during the second quarter valued at $143,000. Teacher Retirement System of Texas bought a new position in shares of Spark Therapeutics during the third quarter valued at $225,000. Prudential Financial Inc. bought a new position in shares of Spark Therapeutics during the third quarter valued at $239,000. Finally, Commonwealth Equity Services Inc bought a new position in shares of Spark Therapeutics during the third quarter valued at $257,000.

Shares of Spark Therapeutics Inc (NASDAQ ONCE) traded up $1.11 on Thursday, reaching $51.34. The company’s stock had a trading volume of 954,100 shares, compared to its average volume of 756,177. The stock has a market capitalization of $1,858.78, a PE ratio of -6.64 and a beta of 3.02. Spark Therapeutics Inc has a fifty-two week low of $41.06 and a fifty-two week high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings results on Tuesday, February 20th. The biotechnology company reported ($1.73) EPS for the quarter, hitting analysts’ consensus estimates of ($1.73). The business had revenue of $7.41 million during the quarter, compared to analysts’ expectations of $9.53 million. Spark Therapeutics had a negative return on equity of 65.56% and a negative net margin of 2,100.80%. equities analysts forecast that Spark Therapeutics Inc will post -4.83 earnings per share for the current fiscal year.

In other Spark Therapeutics news, insider Katherine A. High sold 5,000 shares of the company’s stock in a transaction dated Tuesday, November 28th. The stock was sold at an average price of $71.32, for a total value of $356,600.00. Following the completion of the sale, the insider now owns 215,000 shares in the company, valued at $15,333,800. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 7.30% of the company’s stock.

A number of research firms recently commented on ONCE. Raymond James Financial reiterated a “buy” rating and set a $75.00 price objective on shares of Spark Therapeutics in a research report on Thursday, December 7th. BMO Capital Markets set a $73.00 price objective on Spark Therapeutics and gave the company a “buy” rating in a research report on Tuesday, December 12th. Barclays reiterated a “buy” rating and set a $54.00 price objective on shares of Spark Therapeutics in a research report on Wednesday, December 13th. Cantor Fitzgerald set a $105.00 price objective on Spark Therapeutics and gave the company a “buy” rating in a research report on Wednesday, January 3rd. Finally, ValuEngine cut Spark Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and seventeen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $69.88.

TRADEMARK VIOLATION NOTICE: “Sphera Funds Management LTD. Takes Position in Spark Therapeutics Inc (ONCE)” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/22/sphera-funds-management-ltd-takes-position-in-spark-therapeutics-inc-once.html.

Spark Therapeutics Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics Inc (NASDAQ:ONCE).

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply